CELESTONE SOLUSPAN (nda014602)- (3MG/ML;EQ 3MG BASE/ML)

Generic Name	BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE	Innovator	ORGANON
Dosage	3MG/ML;EQ 3MG BASE/ML
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	Expired	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	When oral therapy is not feasible, the intramuscular use of CELESTONE® SOLUSPAN® Injectable Suspension is indicated as follows: Allergic states, Dermatologic Diseases, Endocrine disorders, Gastrointestinal diseases, Hematologic Disorders, Neoplastic diseases, Nervous system, Ophthalmic diseases, Renal diseases, Respiratory diseases, Rheumatic disorders, etc..

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
2	0	1

Other Developers

Total Other Developers	15

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
3MG/ML;EQ 3MG BASE/ML	**	**	-	1	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	1

Manufacturing Details of CELESTONE SOLUSPAN